clinical trial · NCT04819100
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company·phase3·active not recruiting·n = 152
Carcinoma, Non-Small-Cell LungSelpercatinibPlacebo
brief summary
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.
started
Dec 20, 2021
primary completion
Jan 12, 2026
completion
May 1, 2028
last updated
Mar 4, 2026
official title
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol